Letter from Avidity Biosciences to the FSHD community: March 31st, 2025 Dear FSHD Community, Today, we are very pleased to share with you that we have completed enrollment in the… Read More »
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial
Springbok Analytics Leads MRI Innovations in MOVE Pediatric FSHD Clinical Study
Springbok Analytics Leads MRI Innovations in Multi-Site Pediatric FSHD Clinical Study AI-Driven Muscle Analysis to Support MOVE Peds Study, Advancing Trial Readiness for Pediatric FSHD CHARLOTTESVILLE, Va., March 17, 2025… Read More »
Aiming to access fresh funding for FSHD research
We need YOU – to write to your senators by Anna Gilmore, FSHD Society Last year was an exciting one for our community as we launched our first FSHD Day… Read More »
The fate of the Fulcrum Phase 3 data
This invaluable data is coming to the FSHD Society by Lucienne Ronco, PhD, FSHD Society When a clinical trial fails, what happens to the data? It may include hundreds of… Read More »
European Neuromuscular Centre Conference on Pediatric FSHD
by Ally Roets, Tucson, Arizona I was honored to attend the Pediatric FSHD European Neuromuscular Centre (ENMC) conference in Amsterdam, Netherlands, this past October. I was invited as a parent… Read More »